Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update on acetylsalicylic acid for primary prevention of cardiovascular disease: Not initiating is not the same thing as discontinuing.

Literature DB >> 31300432

Update on acetylsalicylic acid for primary prevention of cardiovascular disease: Not initiating is not the same thing as discontinuing.

Christine Truong¹.

Abstract

Entities: Chemical Disease

Year: 2019 PMID： 31300432 PMCID： PMC6738455

Source DB: PubMed Journal: Can Fam Physician ISSN： 0008-350X Impact factor: 3.275

× No keyword cloud information.

11 in total

1. Low-dose acetylsalicylic acid for primary prevention of cardiovascular disease: Do not misinterpret the recommendations.

Authors: Christine Truong
Journal: Can Fam Physician Date: 2015-11 Impact factor: 3.275

2. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study.

Authors: Johan Sundström; Jakob Hedberg; Marcus Thuresson; Pernilla Aarskog; Kasper Munk Johannesen; Jonas Oldgren
Journal: Circulation Date: 2017-09-26 Impact factor: 29.690

3. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

Authors: Louise Bowman; Marion Mafham; Karl Wallendszus; Will Stevens; Georgina Buck; Jill Barton; Kevin Murphy; Theingi Aung; Richard Haynes; Jolyon Cox; Aleksandra Murawska; Allen Young; Michael Lay; Fang Chen; Emily Sammons; Emma Waters; Amanda Adler; Jonathan Bodansky; Andrew Farmer; Roger McPherson; Andrew Neil; David Simpson; Richard Peto; Colin Baigent; Rory Collins; Sarah Parish; Jane Armitage
Journal: N Engl J Med Date: 2018-08-26 Impact factor: 91.245

4. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors: Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal: Eur Heart J Date: 2016-05-23 Impact factor: 29.983

Review 5. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy.

Authors: Shamir R Mehta; Kevin R Bainey; Warren J Cantor; Marie Lordkipanidzé; Guillaume Marquis-Gravel; Simon D Robinson; Matthew Sibbald; Derek Y So; Graham C Wong; Joseph G Abunassar; Margaret L Ackman; Alan D Bell; Raymond Cartier; James D Douketis; Patrick R Lawler; Michael S McMurtry; Jacob A Udell; Sean van Diepen; Subodh Verma; G B John Mancini; John A Cairns; Jean-François Tanguay
Journal: Can J Cardiol Date: 2017-12-19 Impact factor: 5.223

6. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

Authors: John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray
Journal: N Engl J Med Date: 2018-09-16 Impact factor: 91.245

7. Effect of Aspirin on Disability-free Survival in the Healthy Elderly.

Authors: John J McNeil; Robyn L Woods; Mark R Nelson; Christopher M Reid; Brenda Kirpach; Rory Wolfe; Elsdon Storey; Raj C Shah; Jessica E Lockery; Andrew M Tonkin; Anne B Newman; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Geoffrey A Donnan; Peter Gibbs; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Richard Grimm; Anne M Murray
Journal: N Engl J Med Date: 2018-09-16 Impact factor: 91.245

8. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

Authors: J Michael Gaziano; Carlos Brotons; Rosa Coppolecchia; Claudio Cricelli; Harald Darius; Philip B Gorelick; George Howard; Thomas A Pearson; Peter M Rothwell; Luis Miguel Ruilope; Michal Tendera; Gianni Tognoni
Journal: Lancet Date: 2018-08-26 Impact factor: 79.321

9. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.

Authors: Sean L Zheng; Alistair J Roddick
Journal: JAMA Date: 2019-01-22 Impact factor: 56.272

10. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.

Authors: Giorgia De Berardis; Michele Sacco; Virgilio Evangelista; Alessandro Filippi; Carlo B Giorda; Gianni Tognoni; Umberto Valentini; Antonio Nicolucci
Journal: Trials Date: 2007-08-28 Impact factor: 2.279

3 in total